The packet lists two genes for this condition, TSC1 and TSC2, located on chromosome 9 and chromosome 16 respectively. No ClinGen gene-disease validity classification is supplied for either gene, so the strength of these gene associations is not characterized in this packet. The inheritance pattern recorded in the packet is multifactorial. The packet does not supply further detail on molecular mechanism, recurrence, or penetrance for this condition.

The packet does not supply certified diagnostic methods, biomarkers, or diagnostic criteria for lymphangioleiomyomatosis, and no newborn screening designation is recorded. Diagnostic coverage is therefore not certified in this packet. Two registered studies listed under research have titles that refer to imaging or extracellular vesicle biomarkers in LAM, but a study title does not establish a validated diagnostic approach.

The packet lists three FDA records for sirolimus products with an ACTIVE market status under new drug applications reviewed by CDER: FYARRO (approved 2021-11-22), RAPAMUNE (approved 2000-08-25), and a product listed as SIROLIMUS (approved 1999-09-15). These are the current FDA-approved options recorded in the packet. The orphan drug record for Rapamune, sponsored by Pfizer, Inc., carries the status APPROVED with the indication treatment of lymphangioleiomyomatosis. The packet does not state the indications for the FYARRO or generic sirolimus approval records. Two further sirolimus orphan drug records, sponsored by LAM Therapeutics, Inc. and Cote Orphan Consulting, LLC, are listed as DESIGNATED for the same indication; an orphan designation is not an approval or a statement of availability. Management guidance from the attached GeneReviews chapter is not used, because that chapter addresses tuberous sclerosis complex rather than this condition.

Natural history and prognosis for lymphangioleiomyomatosis are not certified in this packet, and no source-based statement about disease course or outcomes is supplied.

The packet lists registered ClinicalTrials.gov studies that mention lymphangioleiomyomatosis, with most carrying a recruiting or active status. Examples include NCT00001465, a study of the disease process of lymphangioleiomyomatosis sponsored by the National Heart, Lung, and Blood Institute, with a listed beginning date of 1995-12-18 and a recruiting status. NCT01484236 is a national registry in France sponsored by Vincent Cottin, recruiting, with a listed completion date of 2028-12-01. NCT01799538 is a phase 1 study titled as nebulized or inhaled albuterol for lymphangioleiomyomatosis, sponsored by the National Heart, Lung, and Blood Institute and recruiting. NCT06889168 is a phase 1 study titled as long-term safety and tolerability of imatinib in patients with LAM, sponsored by Columbia University and recruiting, with a listed beginning date of 2025-10-20. NCT03150914 is a phase 3 multicenter interventional LAM early disease trial sponsored by the University of Cincinnati, listed as active, not recruiting. NCT02432560, also sponsored by the University of Cincinnati, is titled as safety and durability of sirolimus for treatment of LAM and is listed as recruiting. NCT06160310 is a tuberous sclerosis complex and LAM pregnancy registry sponsored by David M. Ritter. Study titles do not establish the interventions tested or any efficacy.